RxDoctor Payments Data

Jaikirshan Khatri, MD

Interventional Cardiology · New York, NYNPI 1528037165

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boston Scientific at 41.1% of the total. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$306,960in general payments, 2019–2025

Across 573 payments — averaging $535.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$126K
  • Medtronic$44K
  • Shockwave Medical, Inc$37K
  • Abbott$28K
  • Terumo Medical Corporation$27K
  • Asahi Intecc CO., LTD.$13K
  • plus $31K from 22 others
$581,949in research payments, 2019–2025

Across 39 payments — averaging $14,922 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$475K
  • Magenta Medical Inc$34K
  • Cardiovascular Systems Inc.$29K
  • Medtronic$26K
  • Neovasc Medical Inc$17K
  • Asahi Intecc USA, Inc.$1K

What the payments were for

  • Consulting fees$91,23230%
  • Speaking & faculty fees$148,81048%
  • Travel & lodging$42,64814%
  • Food & beverage$23,0928%
  • Education$1,1770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306,960 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$97,470
Medicare patients
323
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$75,009
JardianceEmpagliflozin46$57,424
Repatha SureclickEvolocumab57$39,096
BrilintaTicagrelor50$34,364
EntrestoSacubitril/Valsartan14$15,550
XareltoRivaroxaban21$14,584
Praluent PenAlirocumab19$13,844
Ranolazine ErRanolazine70$5,915
Rosuvastatin Calcium251$4,356
ClopidogrelClopidogrel Bisulfate305$3,814
Metoprolol Succinate170$2,352
Atorvastatin Calcium197$2,048
Isosorbide Mononitrate ErIsosorbide Mononitrate131$1,935
Valsartan22$1,248
Spironolactone-HctzSpironolact/Hydrochlorothiazid34$994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$75,00980 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →